{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:38:26Z","timestamp":1784673506876,"version":"3.55.0"},"reference-count":31,"publisher":"Portland Press Ltd.","issue":"14","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We recently described a new autosomal dominant genetic disorder in a pediatric patient caused by a heterozygous de novo mutation in the ornithine decarboxylase 1 (ODC1) gene. The new genetic disorder is characterized by global developmental delay, alopecia, overgrowth, and dysmorphic features. We hypothesized that this new mutation (c.1342 A&amp;gt;T) leads to a C-terminal truncation variant of the ODC protein that is resistant to normal proteasomal degradation, leading to putrescine accumulation in cells. ODC (E.C. 4.1.1.17) is a rate-limiting enzyme in the biosynthesis of polyamines (putrescine, spermidine, and spermine) that plays a crucial role during embryogenesis, organogenesis, and tumorigenesis. In this study, we show that primary dermal fibroblasts derived from a skin biopsy of a 3-year-old patient contain large amounts of ODC protein and putrescine compared with primary dermal (neonatal and adult) fibroblast control cells. Importantly, the accumulated ODC protein variant remained functionally active as we detected exceptionally high ODC enzyme activity in both primary dermal fibroblasts (12\u201317-fold of controls) and red blood cells (RBCs) (125\u2013137-fold of controls), using a specific 14C radioactive ODC activity assay. Exposure of primary dermal fibroblasts to ODC inhibitor \u03b1-difluoromethylornithine (DFMO) reduced the ODC activity and putrescine to levels observed in controls without adversely affecting cell morphology or inducing cell death. In conclusion, our patient and potentially other patients that carry a similar ODC1 gain-of-function mutation might benefit from treatment with DFMO, a drug with a good safety profile, to suppress the exceptionally high ODC activity and putrescine levels in the body.<\/jats:p>","DOI":"10.1042\/bcj20190294","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T16:49:09Z","timestamp":1561654149000},"page":"2047-2057","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Biochemical features of primary cells from a pediatric patient with a gain-of-function <i>ODC1<\/i> genetic mutation"],"prefix":"10.1042","volume":"476","author":[{"given":"Chad R.","family":"Schultz","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb P.","family":"Bupp","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, U.S.A."},{"name":"Medical Genetics, Spectrum Health and Helen DeVos Children's Hospital, Grand Rapids, MI, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surender","family":"Rajasekaran","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, U.S.A."},{"name":"Pediatric Critical Care Medicine, Helen DeVos Children's Hospital, Grand Rapids, MI, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-8560","authenticated-orcid":false,"given":"Andr\u00e9 S.","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"2021112217595012200_BCJ-2019-0294C1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-018-0050-3","article-title":"Polyamine metabolism and cancer: treatments, challenges and opportunities","volume":"18","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"2021112217595012200_BCJ-2019-0294C2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nrc1454","article-title":"Polyamines and cancer: old molecules, new understanding","volume":"4","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2021112217595012200_BCJ-2019-0294C3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/bj2340249","article-title":"Recent advances in the biochemistry of polyamines in eukaryotes","volume":"234","year":"1986","journal-title":"Biochem. J."},{"key":"2021112217595012200_BCJ-2019-0294C4","doi-asserted-by":"publisher","first-page":"14904","DOI":"10.1074\/jbc.R116.731661","article-title":"Functions of polyamines in mammals","volume":"291","year":"2016","journal-title":"J. Biol. Chem."},{"key":"2021112217595012200_BCJ-2019-0294C5","doi-asserted-by":"publisher","first-page":"C212","DOI":"10.1152\/ajpcell.1982.243.5.C212","article-title":"Polyamine metabolism and function","volume":"243","year":"1982","journal-title":"Am. J. Physiol."},{"key":"2021112217595012200_BCJ-2019-0294C6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1042\/bj2410305","article-title":"Decarboxylation of \u03b1-difluoromethylornithine by ornithine decarboxylase","volume":"241","year":"1987","journal-title":"Biochem. J."},{"key":"2021112217595012200_BCJ-2019-0294C7","volume-title":"GeneReviews((R))","author":"Adam","year":"1993"},{"key":"2021112217595012200_BCJ-2019-0294C8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/sj.ejhg.5201072","article-title":"X-linked spermine synthase gene (SMS) defect: the first polyamine deficiency syndrome","volume":"11","year":"2003","journal-title":"Eur. J. Hum. Genet."},{"key":"2021112217595012200_BCJ-2019-0294C9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/000992286900801114","article-title":"Recessive sex-linked mental retardation in the absence of other recognizable abnormalities. Report of a family","volume":"8","year":"1969","journal-title":"Clin. Pediatr."},{"key":"2021112217595012200_BCJ-2019-0294C10","doi-asserted-by":"publisher","first-page":"E112","DOI":"10.3390\/medsci6040112","article-title":"Polyamine homeostasis in Snyder\u2013Robinson syndrome","volume":"6","year":"2018","journal-title":"Med. Sci."},{"key":"2021112217595012200_BCJ-2019-0294C11","doi-asserted-by":"publisher","first-page":"e2018031","DOI":"10.4322\/acr.2018.031","article-title":"Snyder\u2013Robinson syndrome","volume":"8","year":"2018","journal-title":"Autops. Case Rep."},{"key":"2021112217595012200_BCJ-2019-0294C12","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1002\/ajmg.a.40523","article-title":"Novel de novo pathogenic variant in the ODC1 gene in a girl with developmental delay, alopecia, and dysmorphic features","volume":"176","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"2021112217595012200_BCJ-2019-0294C13","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/ajmg.a.60677","article-title":"Gain-of-function variants in the ODC1 gene cause a syndromic neurodevelopmental disorder associated with macrocephaly, alopecia, dysmorphic features, and neuroimaging abnormalities","volume":"176","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"2021112217595012200_BCJ-2019-0294C14","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1074\/jbc.TM118.003336","article-title":"Polyamine synthesis as a target of MYC oncogenes","volume":"293","year":"2018","journal-title":"J. Biol. Chem."},{"key":"2021112217595012200_BCJ-2019-0294C15","first-page":"4205","article-title":"Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase","volume":"55","year":"1995","journal-title":"Cancer Res."},{"key":"2021112217595012200_BCJ-2019-0294C16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/1523-1747.ep12340155","article-title":"Modulation of murine hair follicle function by alterations in ornithine decarboxylase activity","volume":"106","year":"1996","journal-title":"J. Invest. Dermatol."},{"key":"2021112217595012200_BCJ-2019-0294C17","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1021\/ja00476a050","article-title":"Catalytic irreversible inhibition of mammalian ornithine decarboxylase (E.C.1.1.17) by substrate and product analogs","volume":"100","year":"1978","journal-title":"J. Am. Chem. Soc."},{"key":"2021112217595012200_BCJ-2019-0294C18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo","volume":"56","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"2021112217595012200_BCJ-2019-0294C19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","year":"2009","journal-title":"Lancet"},{"key":"2021112217595012200_BCJ-2019-0294C20","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/jnci\/djq466","article-title":"Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy?","volume":"102","year":"2010","journal-title":"J. Natl Cancer Inst."},{"key":"2021112217595012200_BCJ-2019-0294C21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/1940-6207.CAPR-08-0042","article-title":"Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial","volume":"1","year":"2008","journal-title":"Cancer Prev. Res."},{"key":"2021112217595012200_BCJ-2019-0294C22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-3-642-45195-9_14","article-title":"Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine","volume":"202","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"2021112217595012200_BCJ-2019-0294C23","doi-asserted-by":"publisher","first-page":"e0127246","DOI":"10.1371\/journal.pone.0127246","article-title":"A phase I trial of DFMO targeting polyamine addiction in patients with relapsed\/refractory neuroblastoma","volume":"10","year":"2015","journal-title":"PLoS ONE"},{"key":"2021112217595012200_BCJ-2019-0294C24","doi-asserted-by":"publisher","first-page":"14445","DOI":"10.1038\/s41598-018-32659-w","article-title":"Maintenance DFMO increases survival in high risk neuroblastoma","volume":"8","year":"2018","journal-title":"Sci. Rep."},{"key":"2021112217595012200_BCJ-2019-0294C25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","year":"1990","journal-title":"J. Natl Cancer Inst."},{"key":"2021112217595012200_BCJ-2019-0294C26","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","year":"2006","journal-title":"Nat. Protoc."},{"key":"2021112217595012200_BCJ-2019-0294C27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0021-9673(01)93283-2","article-title":"High-performance liquid chromatographic method for the determination of dansyl-polyamines","volume":"511","year":"1990","journal-title":"J. Chromatogr."},{"key":"2021112217595012200_BCJ-2019-0294C28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1042\/BCJ20170597","article-title":"Synergistic drug combination GC7\/DFMO suppresses hypusine\/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma","volume":"475","year":"2018","journal-title":"Biochem. J."},{"key":"2021112217595012200_BCJ-2019-0294C29","volume-title":"A Guide to the Polyamines","year":"1998"},{"key":"2021112217595012200_BCJ-2019-0294C30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajhg.2018.12.017","article-title":"Recessive rare variants in deoxyhypusine synthase, an enzyme involved in the synthesis of hypusine, are associated with a neurodevelopmental disorder","volume":"104","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"2021112217595012200_BCJ-2019-0294C31","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00726-016-2275-3","article-title":"Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer","volume":"48","year":"2016","journal-title":"Amino Acids"}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/476\/14\/2047\/850421\/bcj-2019-0294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/476\/14\/2047\/850421\/bcj-2019-0294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T02:25:39Z","timestamp":1637634339000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/476\/14\/2047\/219620\/Biochemical-features-of-primary-cells-from-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":31,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019,7,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20190294","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]}}}